Net clinical benefit for oral anticoagulation, aspirin, or no therapy in nonvalvular atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (Beyond Sex)

Journal of the American College of Cardiology

Volumn 66, Issue 4, 2015, Pages 488-490

  Lip, Gregory Y H ^a   Skjøth, Flemming ^a   Rasmussen, Lars Hvilsted ^a   Nielsen, Peter B ^a   Larsen, Torben Bjerregaard ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PHENPROCOUMON; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; LETTER; MALE; MORBIDITY; MORTALITY; NONVALVULR ATRIAL FIBRILLATION; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; VASCULAR DISEASE; COHORT ANALYSIS; COMPLICATION; DENMARK; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COHORT STUDIES; DENMARK; FEMALE; HUMANS; MALE; RISK FACTORS; STROKE; WARFARIN;

EID: 84937723156     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.05.044     Document Type: Letter

References (5)

1. P.B. Nielsen, and T.-F. Chao The risks of risk scores for stroke risk assessment in atrial fibrillation Thromb Haemost 113 2015 1170 1173
2. G.Y.H. Lip, F. Skjøth, L.H. Rasmussen, and et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score J Am Coll Cardiol 65 2015 1385 1394
3. S.J. Connolly, J.W. Eikelboom, J. Ng, and et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable Ann Intern Med 155 2011 579 586
4. L. Friberg, M. Skeppholm, and A. Terént Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 J Am Coll Cardiol 65 2015 225 232
5. J.B. Olesen, and C. Torp-Pedersen Stroke risk in atrial fibrillation: do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher? Thromb Haemost 113 2015 1165 1169